Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn

Executive Summary

The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.

Advertisement

Related Content

Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
Subcutaneous Rituximab Seems Headed For US FDA Advisory Panel OK
Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
Biosimilar Trends: What 2017 May Have In Store
Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing

Topics

Advertisement
UsernamePublicRestriction

Register

PS119708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel